Welcome to PharOS

Developing Value
Supplying Success

PharOS is a privately owned pharmaceutical company, developing, manufacturing and supplying generics and value added products with a global portfolio of more than 68 products and over 6.840 marketing authorizations worldwide.

1 3

Expertise

First to market
Last to Exit

PharOS is a multi-disciplinary organization, in recognition of the numerous different knowledge sets that are required for a proper pharmaceutical product development, registration and supply. Our expertise covers all aspects of product development from API sourcing up to market release.

2 3

The team

Our core competitive
advantage

At PharOS, we have a highly skilled workforce of more than 85 professionals all focused on developing and placing in the market top quality generic and other value added pharmaceuticals that improve the lives of patients to more than 86 countries.

3 3

PRODUCTS
DEVELOPED/UNDER DEVELOPMENT

PRODUCTS LAUNCHED /
UNDER REGISTRATION

Marketing Authorizations
Worldwide

COUNTRY
PRESENCE

OUR MISSION

FIRST TO LAUNCH, LAST TO EXIT

Our mission in PharOS is to materialize in the most efficient way our customers’ trust, by ensuring that their products will be among the first to be launched after patent expiry and the last ones to exit the market.

ABOUT PHAROS

OUR
WORLDWIDE
PRESENCE

MORE THAN 86 COUNTRIES

6845 MARKETING AUTHORIZATIONS

MORE THAN 400 CLIENTS

Presence

ENLARGE MAP

PRODUCTS

Today’s ideas...Tomorrow’s opportunities...

We provide affordable, high-quality medicines to more than 86 countries worldwide

VIEW ALL PRODUCTS

OUR EXPERTS...
our COMPETITIVE
ADVANTAGE

VIEW OUR EXPERTISE

One more successful CPhI (2018)!

See you next year in Frankfurt (CPhI 2019)!

September, 18th 2017

17th Regulatory and Scientific Affairs Conference

17th Regulatory and Scientific Affairs Conference THE LANDMARK LONDON HOTEL, LONDON 25-26 January 2018

March, 28th 2017

PharOS interview at PharmaBoardRoom

The management team of PharOS discuss with PharmaBoardRoom the company’s move from generics consultancy to co-developer, surviving in the Greek market, and internationalization plans.

March, 3rd 2017

European and US regulators agree on mutual recognition of inspections of medicines manufacturers

Regulators in the European Union (EU) and the United States (US) have agreed to recognise inspections of manufacturing sites for human medicines conducted in their respective territories on both sides of the Atlantic.

VIEW ALL NEWS